Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: An overview of the literature

Cancer Treatment Reviews

Volumn 40, Issue 8, 2014, Pages 951-

  Lombardi, Giuseppe ^a   Di Stefano, Anna Luisa ^b,c   Farina, Patrizia ^a   Zagonel, Vittorina ^a   Tabouret, Emeline ^d,e  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c UNIVERSITY OF PAVIA   (Italy)

^d TIMONE HOSPITAL   (France)

^e University of the Mediterranean Aix Marseille II   (France)

Author keywords

Brain metastases; Breast cancer; Lung cancer; Melanoma; Renal cell carcinoma

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR;

BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; DRUG EFFICACY; DRUG SAFETY; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMIC THERAPY;

EID: 84904736573     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2014.05.007     Document Type: Review

References (78)

1. Barnholtz-Sloan J.S., Sloan A.E., Davis F.G., Vigneau F.D., Lai P., Sawaya R.E. Incidence proportions of brain metastases in patients diagnosed (1973-2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 2004, 22:2865-2872.
2. Tabouret E., Chinot O., Metellus P., Tallet A., Viens P., Goncalves A. Recent trends in epidemiology of brain metastases: an overview. Anticancer Res 2012, 32:4655-4662.
3. Cassier P.A., Ray-Coquard I., Sunyach M.P., Lancry L., Guastalla J.P., Ferlay C., et al. A phase 2 trial of whole-brain radiotherapy combined with intravenous chemotherapy in patients with brain metastases from breast cancer. Cancer 2008, 113:2532-2538.
4. Franciosi V., Cocconi G., Michiara M., Di Costanzo F., Fosser V., Tonato M., et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 1999, 85:1599-1605.
5. Siena S., Crino L., Danova M., Del Prete S., Cascinu S., Salvagni S., et al. Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. Ann Oncol 2010, 21:655-661.
6. Rivera E., Meyers C., Groves M., Valero V., Francis D., Arun B., et al. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer 2006, 107:1348-1354.
7. Freedman R.A., Bullitt E., Sun L., Gelman R., Harris G., Ligibel J.A., et al. A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases. Clin Breast Cancer 2011, 11:376-383.
8. Brufsky A.M., Mayer M., Rugo H.S., Kaufman P.A., Tan-Chiu E., Tripathy D., et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res 2011, 17:4834-4843.
9. Lombardi G., Zustovich F., Farina P., Della Puppa A., Manara R., Cecchin D., et al. Neoplastic meningitis from solid tumors: new diagnostic and therapeutic approaches. Oncologist 2011, 16:1175-1188.
10. Colozza M., Minenza E., Gori S., Fenocchio D., Paolucci C., Aristei C., et al. Extended survival of a HER-2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab. Cancer Chemother Pharmacol 2009, 63:1157-1159.
11. Lin N.U., Carey L.A., Liu M.C., Younger J., Come S.E., Ewend M., et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008, 26:1993-1999.
12. Lin N.U., Dieras V., Paul D., Lossignol D., Christodoulou C., Stemmler H.J., et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009, 15:1452-1459.
13. Lin N.U., Eierman W., Greil R., Campone M., Kaufman B., Steplewski K., et al. Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J Neurooncol 2011, 105:613-620.
14. Bachelot T., Romieu G., Campone M., Dieras V., Cropet C., Dalenc F., et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol 2013, 14:64-71.
15. Lin N.U., Freedman R.A., Ramakrishna N., Younger J., Storniolo A.M., Bellon J.R., et al. A phase I study of lapatinib with whole brain radiotherapy in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases. Breast Cancer Res Treat 2013, 142:405-414.
16. Yap Y.S., Cornelio G.H., Devi B.C., Khorprasert C., Kim S.B., Kim T.Y., et al. Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival. Br J Cancer 2012, 107:1075-1082.
17. Gori S., Montemurro F., Spazzapan S., Metro G., Foglietta J., Bisagni G., et al. Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer. Ann Oncol 2012, 23:1436-1441.
18. Kelly K., Bunn P.A. Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer?. Lung Cancer 1998, 20:85-91.
19. Dinglin X.X., Huang Y., Liu H., Zeng Y.D., Hou X., Chen L.K. Pemetrexed and cisplatin combination with concurrent whole brain radiotherapy in patients with brain metastases of lung adenocarcinoma: a single-arm phase II clinical trial. J Neurooncol 2013, 112:461-466.
20. Cortes J., Rodriguez J., Aramendia J.M., Salgado E., Gurpide A., Garcia-Foncillas J., et al. Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer. Oncology 2003, 64:28-35.
21. Kleisbauer J.P., Guerin J.C., Arnaud A., Poirier R., Vesco D. Chemotherapy with high-dose cisplatin in brain metastasis of lung cancers. Bull Cancer 1990, 77:661-665.
22. Quantin X., Khial F., Reme-Saumon M., Michel F.B., Pujol J.L. Concomitant brain radiotherapy and vinorelbine-ifosfamide-cisplatin chemotherapy in brain metastases of non-small cell lung cancer. Lung Cancer 1999, 26:35-39.
23. Neuhaus T., Ko Y., Muller R.P., Grabenbauer G.G., Hedde J.P., Schueller H., et al. A phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer. Br J Cancer 2009, 100:291-297.
24. Giorgio C.G., Giuffrida D., Pappalardo A., Russo A., Santini D., Salice P., et al. Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: phase II study. Lung Cancer 2005, 50:247-254.
25. Kim J.E., Lee D.H., Choi Y., Yoon D.H., Kim S.W., Suh C., et al. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer 2009, 65:351-354.
26. Chiu C.H., Tsai C.M., Chen Y.M., Chiang S.C., Liou J.L., Perng R.P. Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer 2005, 47:129-138.
27. Pesce G.A., Klingbiel D., Ribi K., Zouhair A., von Moos R., Schlaeppi M., et al. Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03). Eur J Cancer 2012, 48:377-384.
28. Ma S., Xu Y., Deng Q., Yu X. Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and gefitinib in a Chinese population. Lung Cancer 2009, 65:198-203.
29. Hsiao S.H., Lin H.C., Chou Y.T., Lin S.E., Kuo C.C., Yu M.C., et al. Impact of epidermal growth factor receptor mutations on intracranial treatment response and survival after brain metastases in lung adenocarcinoma patients. Lung Cancer 2013, 81:455-461.
30. Welsh J.W., Komaki R., Amini A., Munsell M.F., Unger W., Allen P.K., et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol 2013, 31:895-902.
31. Bai H., Han B. The effectiveness of erlotinib against brain metastases in non-small cell lung cancer patients. Am J Clin Oncol 2013, 36:110-115.
32. Ceresoli G.L., Cappuzzo F., Gregorc V., Bartolini S., Crino L., Villa E. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol 2004, 15:1042-1047.
33. Wu C., Li L.Y., Wang M.Z., Zhang L., Zhang X.T., Zhong W., et al. Gefitinib in the treatment of advanced non-small cell lung cancer with brain metastasis. Zhonghua Zhong Liu Za Zhi 2007, 29:943-945.
34. Soffietti R., Trevisan E., Ruda R. Targeted therapy in brain metastasis. Curr Opin Oncol 2012, 24:679-686.
35. Socinski M.A., Langer C.J., Huang J.E., Kolb M.M., Compton P., Wang L., et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol 2009, 27:5255-5261.
36. Ichiki M., Yoshida T., Nakamura M., Kumano T., Hoshino T. Efficacy and safety of bevacizumab in nonsquamous non-small cell lung cancer with brain metastases. J Clin Oncol 2013, 31. suppl; abstr e19134.
37. Zustovich F., Ferro A., Lombardi G., Zagonel V., Fiduccia P., Farina P. Bevacizumab as front-line treatment of brain metastases from solid tumors: a case series. Anticancer Res 2013, 33:4061-4065.
38. Noroxe D.S., Wallerek S., Sorensen J.B. Platinum-based doublet chemotherapy plus bevacizumab without bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC). Anticancer Res 2013, 33:3275-3278.
39. Jacquillat C., Khayat D., Banzet P., Weil M., Fumoleau P., Avril M.F., et al. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 1990, 66:1873-1878.
40. Avril M.F., Aamdal S., Grob J.J., Hauschild A., Mohr P., Bonerandi J.J., et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004, 22:1118-1125.
41. Mornex F., Thomas L., Mohr P., Hauschild A., Delaunay M.M., Lesimple T., et al. A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res 2003, 13:97-103.
42. Margolin K., Atkins B., Thompson A., Ernstoff S., Weber J., Flaherty L., et al. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol 2002, 128:214-218.
43. Atkins M.B., Sosman J.A., Agarwala S., Logan T., Clark J.I., Ernstoff M.S., et al. Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. Cancer 2008, 113:2139-2145.
44. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
45. Robert C., Thomas L., Bondarenko I., O'Day S., Weber J., Garbe C., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364:2517-2526.
46. Hodi F.S., Oble D.A., Drappatz J., Velazquez E.F., Ramaiya N., Ramakrishna N., et al. CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol 2008, 5:557-561.
47. Bot I., Blank C.U., Brandsma D. Clinical and radiological response of leptomeningeal melanoma after whole brain radiotherapy and ipilimumab. J Neurol 2012, 259:1976-1978.
48. Schartz N.E., Farges C., Madelaine I., Bruzzoni H., Calvo F., Hoos A., et al. Complete regression of a previously untreated melanoma brain metastasis with ipilimumab. Melanoma Res 2010, 20:247-250.
49. Di Giacomo A.M., Ascierto P.A., Pilla L., Santinami M., Ferrucci P.F., Giannarelli D., et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol 2012, 13:879-886.
50. Margolin K., Ernstoff M.S., Hamid O., Lawrence D., McDermott D., Puzanov I., et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012, 13:459-465.
51. Queirolo P., Spagnolo F., Ascierto P.A., Simeone E., Marchetti P., Scoppola A., et al. Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. J Neurooncol 2014, 118:109-116.
52. Long G.V., Menzies A.M., Nagrial A.M., Haydu L.E., Hamilton A.L., Mann G.J., et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011, 29:1239-1246.
53. Thomas N.E., Edmiston S.N., Alexander A., Millikan R.C., Groben P.A., Hao H., et al. Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma. Cancer Epidemiol Biomarkers Prev 2007, 16:991-997.
54. Falchook G.S., Long G.V., Kurzrock R., Kim K.B., Arkenau T.H., Brown M.P., et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012, 379:1893-1901.
55. Long G.V., Trefzer U., Davies M.A., Kefford R.F., Ascierto P.A., Chapman P.B., et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012, 13:1087-1095.
56. Dummer R., Goldinger S.M., Turtschi C.P., Eggmann N.B., Michielin O., Mitchell L., et al. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer 2014, 50:611-621.
57. Klein O., Clements A., Menzies A.M., O'Toole S., Kefford R.F., Long G.V. BRAF inhibitor activity in V600R metastatic melanoma. Eur J Cancer 2013, 49:1073-1079.
58. Mittapalli R.K., Vaidhyanathan S., Dudek A.Z., Elmquist W.F. Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. J Pharmacol Exp Ther 2013, 344:655-664.
59. Flaherty K.T., Infante J.R., Daud A., Gonzalez R., Kefford R.F., Sosman J., et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012, 367:1694-1703.
60. Sullivan R.J., Lawrence D.P., Wargo J.A., Oh K.S., Gonzalez R.G., Piris A. Case records of the Massachusetts General Hospital. Case 21-2013. A 68-year-old man with metastatic melanoma. N Engl J Med 2013, 369:173-183.
61. Mole R.H. Whole body irradiation; radiobiology or medicine?. Br J Radiol 1953, 26:234-241.
62. Schouten L.J., Rutten J., Huveneers H.A., Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 2002, 94:2698-2705.
63. Decker D.A., Decker V.L., Herskovic A., Cummings G.D. Brain metastases in patients with renal cell carcinoma: prognosis and treatment. J Clin Oncol 1984, 2:169-173.
64. Shuch B., La Rochelle J.C., Klatte T., Riggs S.B., Liu W., Kabbinavar F.F., et al. Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival. Cancer 2008, 113:1641-1648.
65. Hu S., Chen Z., Franke R., Orwick S., Zhao M., Rudek M.A., et al. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res 2009, 15:6062-6069.
66. Gore M.E., Szczylik C., Porta C., Bracarda S., Bjarnason G.A., Oudard S., et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009, 10:757-763.
67. Gore M.E., Hariharan S., Porta C., Bracarda S., Hawkins R., Bjarnason G.A., et al. Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer 2011, 117:501-509.
68. Stadler W.M., Figlin R.A., McDermott D.F., Dutcher J.P., Knox J.J., Miller W.H., et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 2010, 116:1272-1280.
69. Massard C., Zonierek J., Gross-Goupil M., Fizazi K., Szczylik C., Escudier B. Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Ann Oncol 2010, 21:1027-1031.
70. Verma J., Jonasch E., Allen P., Tannir N., Mahajan A. Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma. Cancer 2011, 117:4958-4965.
71. Bastos D., Molina A.M., Jia X., Velasco S., Patil S., Voss M.H., et al. Targeted therapy for renal cell carcinoma with brain metastasis: overall survival and safety. J Clin Oncol 2013, 31. suppl; abstr e15517.
72. Larkin J.M., Hess V., Pickering L.M., Ferguson T., Forrest R., Gore M.E. Symptomatic brain metastases from renal cell carcinoma during treatment with sunitinib or sorafenib. J Clin Oncol 2010, 28. suppl; abstr e15023.
73. Verma J., Jonasch E., Allen P.K., Weinberg J.S., Tannir N., Chang E.L., et al. The impact of tyrosine kinase inhibitors on the multimodality treatment of brain metastases from renal cell carcinoma. Am J Clin Oncol 2013, 36:620-624.
74. Jacobs C., Kim D.W., Straka C., Timmerman R.D., Brugarolas J. Prolonged survival of a patient with papillary renal cell carcinoma and brain metastases using pazopanib. J Clin Oncol 2013, 31:e114-e117.
75. Vickers M.M., Al-Harbi H., Choueiri T.K., Kollmannsberger C., North S., Mackenzie M., et al. Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium. Clin Genitourin Cancer 2013, 11:311-315.
76. Zustovich F., Ferro A., Farina P. Bevacizumab as first-line therapy for patients with brain metastases from renal carcinoma: a case series. Clin Genitourin Cancer 2014, 12:e107-e110.
77. Cotto C., Berille J., Souquet P.J., Riou R., Croisile B., Turjman F., et al. A phase II trial of fotemustine and cisplatin in central nervous system metastases from non-small cell lung cancer. Eur J Cancer 1996, 32A:69-71.
78. Fujita A., Fukuoka S., Takabatake H., Tagaki S., Sekine K. Combination chemotherapy of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with brain metastases from non-small cell lung cancer. Oncology 2000, 59:291-295.